Table 1.
Baseline data of the overall study cohort.
| Variable | Laser-Balloon N = 50 |
Radiofrequency N = 50 |
p-Value |
|---|---|---|---|
| Demographics | |||
| Age—years | 63 (54–68) | 61 (53–65) | 0.201 |
| Male sex—no. (%) | 35 (70) | 35 (70) | 1 |
| BMI—kg/m2 | 26.4 (23.6–30.0) | 26.2 (24.0–30.2) | 0.890 |
| Comorbidities | |||
| Hypertension—no. (%) | 18 (36) | 21 (42) | 0.682 |
| Diabetes—no. (%) | 3 (6) | 1 (2) | 0.617 |
| Dyslipidemia—no (%) | 8 (16) | 19 (38) | 0.023 |
| CHA2DS2-VASc Score | 1 (0–2) | 1 (0–3) | 0.627 |
| Active smoking—no. (%) | 4 (8) | 10 (20) | 0.148 |
| Obstructive sleep apnea—no. (%) | 4 (8) | 6 (12) | 0.739 |
| COBP—no (%) | 5 (10) | 1 (2) | 0.204 |
| Obesity—no (%) | 14 (28) | 13 (26) | 1 |
| Stroke—no (%) | 1 (2) | 5 (10) | 0.204 |
| HFrEF—no. (%) | 4 (8) | 3 (6) | 1 |
| Coronary artery disease—no (%) | 2 (4) | 8 (16) | 0.092 |
| Renal failure—no (%) | 3 (6) | 3 (6) | 1 |
| Previous Medication | |||
| B-blocker—no (%) | 25 (50) | 24 (48) | 1 |
| Amiodarone—no (%) | 17 (34) | 20 (40) | 0.534 |
| Flecainide—no (%) | 24 (48) | 20 (40) | 0.420 |
| Sotalol—no (%) | 5 (10) | 2 (4) | 0.436 |
| Echocardiography features | |||
| LVEF—% | 60 (55–65) | 60 (56–65) | 0.908 |
| LVEF < 50%—no (%) | 3 (6) | 1 (2) | 0.617 |
| Left atrial dilatation—no (%) | 22 (44) | 22 (44) | 1 |
| Left atrial surface area—cm2 | 20 (17–23.5) | 20.5 (16.9–24) | 0.861 |
| Left atrial volume indexed—mL/m2 | 33 (25–40) | 32.9 (27.2–40.6) | 0.532 |
BMI: body mass index; COBP: chronic obstructive broncho-pneumopathy; HRrEF: heart failure with reduced ejection fraction; LVEF: left ventricular ejection fraction.